Factors Associated with Severe Outcomes Among Immunocompromised Adults Hospitalized for COVID-19 — COVID-NET, 10 States, March 2020–February 2022

Abstract

Vaccinated patients were defined as those with a positive SARS-CoV-2 test result from a specimen collected 14 days after either the second dose of a 2-dose vaccination series or after 1 dose of a single-dose vaccine. When not otherwise specified, vaccinated patients include those who might have received additional or booster doses. Vaccinated patients without additional or booster doses include both those eligible and those not yet eligible for an additional or booster dose. Vaccinated patients with additional booster doses received additional or booster doses on or after August 13, 2021, with a positive SARS-CoV-2 test result from a specimen collected 14 days after receipt of additional or booster doses. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/ immuno.html https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/peoplewith-medical-conditions.html; https://www.covid19treatmentguidelines.nih. gov/overview/prioritization-of-therapeutics/ ** California, Colorado, Connecticut, Georgia, Michigan, Minnesota, New Mexico, New York, Oregon, and Tennessee. Data from four other states in COVID-NET were not available for this analysis. Excluded admissions for labor/obstetrics, trauma, psychiatric conditions, or inpatient surgery. Standardized COVID-NET medical chart abstraction identified the following immunocompromising conditions: AIDS or CD4+ count <200, complement deficiency, graft versus host disease, HIV infection, immunoglobulin deficiency/immunodeficiency, immunosuppressive therapy (within 12 months before admission), leukemia, Hodgkin or non-Hodgkin lymphoma, metastatic cancer, multiple myeloma, solid organ malignancy, steroid therapy (within 2 weeks of admission), and transplant history involving hematopoietic stem cells or solid organs.